Catalyst
Slingshot members are tracking this event:
AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV |
|
|
||||
Additional Information
- Trial will study efficacy and safety of venetoclax in combination with bortezomib and dexamethasone in patients who are considered sensitive or naïve to proteasome inhibitors who have received 1 to 3 prior lines of therapy for multiple myeloma(1)
- Multiple myeloma is a cancer formed by malignant plasma cells and is the second most common type of blood cancer(2)
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Venetoclax, Refractory Multiple Myeloma
